Belimumab: Seizures and cytokine release syndrome.

A clinical analysis involving 10 patients with acute B-lymphoblastic leukaemia (B-ALL) found that two patients developed seizures or cytokine release syndrome during treatment with belimumab (belintoumab). One patient experienced grade 2 seizures, while the other patient experienced grade 2 cytokine release syndrome. The analysis did not provide information on the patients' age, sex, dosages, routes of administration, duration of treatment, or outcomes. [Extracted from the article]